Avecourt - instructions for use, dose, side effects, contraindications

Auxiliary substances: propylene glycol - 12.0 g, purified water 3.0 g, glyceryl monostearate 2.0 g, emulsion wax 5.0 g, petroleum jelly 77.9 g, phosphoric acid up to pH 3.0 -7.5.

Description:

Ointment from white to white with a yellowish tint of color with a weak specific odor.

Pharmacotherapeutic group:Glucocorticosteroid for topical application

ATX: & nbsp

Pharmacodynamics:

GCS for topical application. Has anti-inflammatory and anti-allergic effect. It inhibits the release of inflammatory mediators. Increases the production of lipocortin, which is an inhibitor of phospholipase A2, which causes a decrease in the formation of arachidonic acid. It prevents the accumulation of neutrophils, which reduces inflammatory exudate and production of cytokines, inhibits the migration of macrophages, leads to a decrease in the processes of infiltration and granulation. Reduces inflammation due to a decrease in the formation of the chemotaxis substance (effect on the "late" allergy reaction), inhibits the development of an "immediate" allergic reaction (due to inhibition of the production of arachidonic acid metabolites and a decrease in the release of inflammatory mediators from mast cells).

Pharmacokinetics:The absorption of mometasone from 0.1% of the ointment through the normal skin is 0.4% of the dose for 8 hours after the application without bandage. In case of inflammation or damage to the skin, absorption accelerates.

Indications:

Inflammation and itching of the skin with dermatoses (including psoriasis, atopic dermatitis), in which treatment with SCS is indicated.

Contraindications:Hypersensitivity to any component of the drug or to other GCS. Pink acne, perioral dermatitis. Bacterial, viral (Herpes simplex, Herpes zoster) or fungal infection of the skin. Tuberculosis, syphilis. Post-vaccination reactions. Pregnancy (treatment of extensive skin areas, long-term treatment). Lactation period (use in large doses and / or for a long time). Children under 2 years.

Carefully:

Applying to the face skin and intertriginoznuyu surface of the skin, the use of occlusive dressings, as well as the treatment of large areas of the skin and / or long-term treatment (especially in children).

Pregnancy and lactation:

The safety of mometasone during pregnancy and lactation has not been studied. GCS penetrate the placental barrier. Long-term treatment and use of large doses during pregnancy and due to the threat of adverse effects on fetal development should be avoided. GCS is excreted in breast milk. In the event that the use of GCS is expected in large doses and / or for a long time, breastfeeding should be discontinued.

Dosing and Administration:Outwardly. A thin layer of ointment is applied to the affected areas of the skin once a day. Duration of treatment: 7-28 days, determined by the effectiveness of therapy, as well as the patient's tolerance of the patient, the presence and severity of side effects.

Side effects:Local reactions: burning, itching, paresthesia, folliculitis, acnerash, skin atrophy, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin maceration, attachment of secondary infection, striae, sweating. The probability of occurrence of the listed undesirable phenomena increases at the use of occlusive dressings.
Systemic action: When external forms of SCS are used for a long time and / or for the treatment of large areas of the skin (the total area of application is larger than the palm of the patient), or with the use of occlusive dressings, especially in children and adolescents, side effects / system action,including adrenal insufficiency and Isenko-Cushing syndrome.

Overdose:

Symptoms: oppression of hypothalamic-pituitary- adrenal system (including secondary adrenal insufficiency).

Treatment symptomatic. If necessary - correction of electrolyte imbalance, drug withdrawal (with prolonged therapy - gradual cancellation).

Interaction:

Interactions with other drugs have not been described to date. By chemical properties mometasone furoate is incompatible with alkalis.

Special instructions:

If there is no effect within 2 weeks of therapy, the diagnosis should be clarified. When applied to large areas of the skin for a long time, especially when using occlusive dressings, it is possible to develop a systemic effect of GCS.

Given this, it is necessary to monitor the function of the hypothalamic-pituitary-adrenal system. Propylene glycol, which is part of the preparation, may cause irritation at the site of application. In such cases, discontinue use of the drug and prescribe appropriate treatment.

It should be borne in mind that SCS is able to change the manifestation of certain skin diseases, which can complicate the diagnosis. In addition, the use of GCS may be the cause of delayed wound healing.

With prolonged therapy with SCS, sudden discontinuation of therapy can lead to the development of a rebound syndrome, manifested in the form of dermatitis with intense reddening of the skin and a burning sensation. Therefore, after a long course of treatment, the drug should be canceled gradually, for example, by switching to an intermittent treatment regimen before it is completely discontinued.

Pediatric use: Due to the fact that the ratio of surface area and body weight is greater in children than in adults, children are at greater risk of suppressing the function of the hypothalamic-pituitary-adrenal system and the development of the Itenko-Cushing syndrome with any local GCS. Long-term treatment of children with SCS can lead to disruption of their growth and development. The use of the drug in children for more than 3 weeks has not been studied.

Children should receive a minimum dose of the drug sufficient to achieve the effect.

Effect on the ability to drive transp. cf. and fur:Data on the adverse effects of the drug on the ability to drive vehicles and work with mechanisms are not available.

Form release / dosage:

Ointment for external use 0,1%.

Packaging:For 15 g or 30 g in tubes are aluminum. Each tube, together with instructions for medical use, is placed in a pack of cardboard.

Storage conditions:

In a dry place at a temperature of 2 to 30 ° C.

Shelf life:

3 years. Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:LP-001041

Date of registration:21.10.2011

Expiration Date:21.10.2016

The owner of the registration certificate:PATENT-FARM, CJSC PATENT-FARM, CJSC Russia

Manufacturer: & nbsp

GREEN DUBRAVA, CJSC Russia

Information update date: & nbsp21.01.2017

Illustrated instructions

Instructions

Avecourt (Avekort)